BiotechTube

SP-103 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate to Severe Acute Lower Back Pain

Conditions

Moderate to Severe Acute Lower Back Pain

Trial Timeline

Apr 29, 2022 → May 30, 2023

NCT ID
NCT05096494

About SP-103 + Placebo

SP-103 + Placebo is a phase 2 stage product being developed by Scilex Holding for Moderate to Severe Acute Lower Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT05096494. Target conditions include Moderate to Severe Acute Lower Back Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05096494Phase 2Completed

Competing Products

20 competing products in Moderate to Severe Acute Lower Back Pain

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
80
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
PexidartinibDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
tacrolimusAstellas PharmaApproved
85
AlefaceptAstellas PharmaApproved
85
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
52
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
77
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
65
Ranirestat + PlaceboEisaiPhase 2/3
65
E6007 + PlaceboEisaiPhase 2
52
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827 + PlaceboKyowa KirinPhase 3
77
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
85
KHK4827 + PlaceboKyowa KirinPhase 2
52
Stelara + Bmab1200BioconPhase 3
77

Other Products from Scilex Holding

Lidocaine 1.8% + PlaceboApproved
77
SP-102 + PlaceboPhase 3
69
SP-102Phase 2
44
ZTlido (Lidocaine Topical System) 1.8% + Salonpas (Lidocaine Patch 4%) + Aspercreme (Lidocaine Patch 4%) + IcyHot (Lidocaine 4% + Menthol 1% Patch)Phase 1
25
lidocaine topical system 1.8% + lidocaine patch 5%Phase 1
25